Viking Therapeutics, Inc. (LON:0VQA)

Viking Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	53.39	49.28	37.02	16.12	10.7	10.73
Research & Development	118.93	101.64	63.81	54.23	44.98	31.93
Operating Expenses	172.32	150.92	100.83	70.36	55.68	42.66
Operating Income	-172.32	-150.92	-100.83	-70.36	-55.68	-42.66
Interest Expense	-0.09	-0.09	-0.09	-0.06	-0.02	-0.11
Interest & Investment Income	44.06	40.94	15.02	1.59	0.7	3.23
Currency Exchange Gain (Loss)	-	-	-	-	0.01	-
EBT Excluding Unusual Items	-128.35	-110.08	-85.9	-68.83	-54.99	-39.54
Gain (Loss) on Sale of Investments	0.11	0.11	-	-0.04	-	0.04
Pretax Income	-128.24	-109.96	-85.9	-68.87	-54.99	-39.5
Net Income	-128.24	-109.96	-85.9	-68.87	-54.99	-39.5
Net Income to Common	-128.24	-109.96	-85.9	-68.87	-54.99	-39.5
Shares Outstanding (Basic)	111	109	94	77	77	73
Shares Outstanding (Diluted)	111	109	94	77	77	73
Shares Change (YoY)	10.50%	15.57%	22.79%	-0.47%	6.34%	0.89%
EPS (Basic)	-1.15	-1.01	-0.91	-0.90	-0.71	-0.54
EPS (Diluted)	-1.15	-1.01	-0.91	-0.90	-0.71	-0.54
EBIT	-172.32	-150.92	-100.83	-70.36	-55.68	-42.66

Source: S&P Global Market Intelligence. Standard template. Financial Sources.